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Vascular smoothmuscle cells (SMCs),which arise frommultiple embryonic progenitors, have unique lineage-specific
properties and this diversity may contribute to spatial patterns of vascular diseases. We developed in vitro methods to
generate distinct vascular SMC subtypes from human pluripotent stem cells, allowing us to explore their intrinsic
differences and the mechanisms involved in SMC development. Since Notch signaling is thought to be one of the
several key regulators of SMCdifferentiation and function, we profiled the expression of Notch receptors, ligands, and
downstream elements during the development of origin-specific SMC subtypes. NOTCH3 expression in our in vitro
model varied in a lineage- and developmental stage-specificmanner so that the highest expression inmature SMCswas
in those derived fromparaxialmesoderm (PM). This patternwas consistentwith the high expression level ofNOTCH3
observed in the 8–9weekhuman fetal descending aorta,which is populated bySMCsof PMorigin. SilencingNOTCH3
in mature SMCs in vitro reduced SMC markers in cells of PM origin preferentially. Conversely, during early devel-
opment, NOTCH3 was highly expressed in vitro in SMCs of neuroectoderm (NE) origin. Inhibition of NOTCH3 in
early development resulted in a significant downregulation of specific SMC markers exclusively in the NE lineage.
Corresponding to this prediction, the Notch3-null mouse showed reduced expression of Acta2 in the neural crest-
derived SMCs of the aortic arch. Thus, Notch3 signaling emerges as one of the key regulators of vascular SMC
differentiation and maturation in vitro and in vivo in a lineage- and temporal-dependent manner.
Introduction
Aprimary role of mature vascular smooth muscle cells(SMCs) is to maintain vascular tone and regulate blood
pressure and blood flow distribution through constriction and
dilation of the vessels [1]. In adult organisms, SMCs show
extensive differences in morphology and function and these
may depend on their position in the vascular bed, the organ
context, and their embryological origin. Furthermore, adult
vascular SMCs still maintain a remarkable phenotypic plas-
ticity by undergoing profound and reversible changes, such
as proliferation, migration, and downregulation of contractile
genes, following vascular injury or disease [2].
Importantly, the origin of SMCs within the major arteries
of the trunk is complex with contributions from several in-
dependent cell lineages. In particular, SMCs of the devel-
oping aortic arch, ductus arteriosus, pulmonary trunk, and
the proximal regions of the major aortic arch branches de-
rive from the cardiac neural crest [3–5], while the second
heart field (lateral mesoderm [LM] origin) gives rise to SMCs
at the root of the aorta, and the somites [paraxial mesoderm
(PM) origin] generate SMCs of the descending aorta [6,7].
It is known that vascular SMC subtypes show lineage-spe-
cific differences in growth, gene expression, and functional
properties [8], and these differences may contribute to site-
specific patterns of vascular diseases, such as aortic aneurysm.
Tobetter comprehend the intrinsic differences betweenorigin-
specific SMC lineages and to study the role that specific signaling
pathwaysplay in each lineage, our grouphasgenerated an invitro
model for lineage-specific vascular SMCs originating from hu-
man pluripotent stem cells [9]. Origin-specific SMCs derived
using this system replicate many of the known differences be-
tween SMCs of different lineages, such as response toTGF-b1 or
requirement forMKL/myocardin-like 2 (MKL2) indevelopment
[9]. Moreover, this in vitro model correctly predicted the pro-
teolytic properties of different tissue-derived vascular SMCs.
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For the studies in the present article, we have focused our
attention on the Notch pathway, which is known to play a
key role in cardiovascular development, vascular repair of
injury, and vascular pathology in humans [10,11]. Vascular
SMCs express multiple Notch receptors, which are known to
regulate smooth muscle differentiation, recruitment to
growing vessels, and maturation. However, little is known
about the involvement of distinct Notch family members in
SMC lineages with different embryological origins.
Notch receptors are type-1 transmembrane proteins, which
are activated upon interaction with two families of ligands:
Jagged ( JAG) or Delta-like (DLL) [12,13]. In mammals, the
expression of four Notch receptors (NOTCH1, NOTCH2,
NOTCH3, and NOTCH4) and five Jagged or Delta-like li-
gands ( JAG1, JAG2, DLL1, DLL3, and DLL4) varies among
cell types and changes in response to environmental cues
within the surrounding tissue. Upon ligand interaction, Notch
receptors undergo cleavage events and the soluble Notch in-
tracellular domain (NICD) is released and translocates to the
nucleus, where it forms an active transcriptional complex
with the DNA-binding protein CSL (CBF-1/RBP-Jk, Su(H),
and Lag-1). This complex regulates downstream gene ex-
pression, including members of the HES (hairy/enhancer of
split) and HRT (Hairy-related, also referred to as HEY,
HERP, HESR, CHF) families [14].
Studies investigating the function of Notch signaling in
vascular SMCs have shown contradictory results, describing
both antidifferentiation [15,16] and prodifferentiation functions
for Notch [17–20]. These contradictory results may be due to
the context-dependent nature of potential inhibitory feedback
byHRT family members and tight spatiotemporal regulation of
Notch components during development. To help resolve this
controversy, additional studies are essential, which aim to
identify the expression pattern of different Notch ligands and
receptors, the specificity of the ligands to the Notch receptors,
and activation of downstream targets during SMCdevelopment
and in the mature state. Importantly, it has been proposed that
vascular SMCs of diverse embryonic origins have unique reg-
ulatorymechanisms of differentiation; therefore, it is important
to examine the expression of Notch pathway components and
their potential role in each distinct SMC subtype.
In this study, we show that expression of Notch receptors, in
particular NOTCH3, ligands, and effectors varies during the
development of origin-specific vascular SMC lineages in a lin-
eage- and time-dependent manner. In addition, we demonstrate
that specific inhibition of NOTCH3 causes downregulation of
SMC markers in both paraxial mesoderm-derived SMCs (PM-
SMCs) and neuroectoderm-derived SMCs (NE-SMCs) when
the cells are fully differentiated, but only in SMCs of neu-
roectoderm (NE) origin at an early stage of development. Im-
portantly, we then validate our novel in vitro findings using
human fetal aortic tissues and a Notch3-null mouse model,
suggesting that our human embryonic stem cell (hESC)-derived
system closely mimics vascular SMC development in vivo.
Materials and Methods
Cell culture
Human H9 ESCs (passages 65–85) were cultured in a
chemically defined medium (CDM) as previously described
[21]. Human induced pluripotent stem cells (hiPSCs) were ob-
tained from the Cambridge Biomedical Research Centre iPSC
Core Facility and grown on irradiated mouse feeders in typical
DMEM/F12 medium containing 20% knockout serum re-
placement (Gibco) and 4ng/mL FGF-2 (R&D System). hESCs
and hiPSCs were differentiated into the three intermediate
populations as described in Cheung et al. 2012 [9]. After ob-
taining the intermediate populations, cells were trypsinized and
cultured in SMC differentiation medium CDM contain-
ing PDGF-BB (10ng/mL, PeproTech) and TGF-b1 (2 ng/mL,
PeproTech) for at least 12 days. For long-term cultures, SMCs
were grown inMEMmedium (M5650; Sigma) containing 10%
fetal bovine serum (FBS, F7524; Sigma) for up to 30 days.
Quantitative real-time polymerase chain reaction
Developing SMCs were harvested at different time points
before and during PDGF-BB and TGF-b1 treatment, and
mature SMCs were harvested after 30 days of serum-contained
medium culture. Whole heart and aorta were harvested from 8-
to 9-week-old human fetal tissue (n=2; REC 96/085) obtained
following therapeutic pregnancy interruption performed at
Cambridge University Hospitals NHS Foundation Trust with
ethical approval and informed consent. Aortic tissue was
subsectioned into ascending aorta (AA), descending thoracic
aorta (DTA), descending abdominal aorta (DAA), and pul-
monary artery (PA) tissue. Tissues were homogenized in RLT
buffer (Qiagen) utilizing Lysing Matrix D-Tubes (Anachem)
and a Bio 101 FastPrep FP120 (Savant). Total RNA was ex-
tracted with the RNeasy Mini kit according to the manufac-
turer’s instructions (Qiagen). cDNA was synthesized from
250ng of RNA using the Maxima First Strand cDNA Synth-
esis Kit (Thermo Scientific). Quantitative real-time poly-
merase chain reaction (qRT-PCR) mixtures were prepared
with SYBR GreenER PCR Super Mix (Invitrogen) and
the reactions were performed in technical duplicates with the
Rotor-gene 6000 system (Corbett Life Science), using the
Quantitation–comparative CT settings. Primer sequences are
listed in Supplementary Table S1 (Supplementary Data are
available online at www.liebertpub.com/scd).
Flow cytometry
For flowcytometry ofNOTCH3, SMCswere harvested at the
developing stage of day 12 for LM- and PM-SMCs and day 14
for NE-SMCs and at the mature stage after 30 days of serum-
containedmedium culture. SMCs transfected once or twice with
specificNotch3 siRNAor scrambled siRNAwere harvested 48h
after transfection. SMCs were fixed using the Cytofix/Cyto-
perm Fixation/Permeabilization kit (BD Biosciences) and
stained according to the kit manual. Fixed SMCs were stained
with rabbit polyclonal anti-NOTCH3antibody 1:200 (ab23426;
Abcam) for 1 h at 4C, followed by two washes with the Cy-
towash buffer, and then incubated with a goat anti-rabbit Alexa
Fluor 488 antibody for 30 s at 4C, followed by twowasheswith
the Cytowash buffer. Rabbit IgG isotope control (Sigma) was
used. Cells were then resuspended in phosphate-buffered saline
(PBS) and measured with Cyan ADP cell analyzer. Flow cy-
tometric data were analyzed with FlowJo vX software.
Cryosectioning and Immunohistochemistry
Whole aortas dissected from 8- to 9-week-old human fetal
tissue (n= 3) were fixed in 4% paraformaldehyde in PBS for
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4–5 h at 4C. Each sample was cryoprotected by consecutive
incubation in 25% and 50% sucrose in PBS overnight. Then,
the tissue was infiltrated with OCT medium, reoriented in-
side cryostat molds, and snap-frozen in liquid nitrogen.
Embedded tissue was sectioned at 10 mm with a Cryostar
NX70 cryostat (Thermo Scientific). Individual tissue sec-
tions were transferred to Superfrost Plus microscope slides
(Fisher Scientific) and stored at - 20C. Tissue sections
were rehydrated in PBS, followed by incubation with
blocking solution [10% FBS and 1% bovine serum albumin
(BSA) in PBS] for 1 h at room temperature. Serial sections
were then incubated with primary antibodies, polyclonal
rabbit anti-NOTCH3 1:200 and monoclonal antismooth
muscle a-actin, ACTA2 1:400 (F3777; Sigma), overnight at
4C. The sections were then washed in PBS and stained with
secondary goat anti-mouse Alexa Fluor 568 and goat anti-
rabbit Alexa Fluor 488 antibodies (Invitrogen Molecular
Probes) for 1 h at room temperature. After PBS washing, the
slides were mounted with aqueous mounting medium
(VectaMount; Vector Laboratories) and coverslipped.
Human aorta staining quantification
Images were acquired using 5X objective on a Zeiss Ax-
iovert 200M epifluorescence microscope and 20X objective
on a Zeiss Observer Z1 LSM 700 confocal microscope (three
images of each aortic area for three different aortas were
examined). All the images were collected with the same
setting. Fluorescent images were analyzed with ImageJ soft-
ware. The intensity of Notch3 staining in human sections was
normalized to the one of DTA on the same section to correct
for intersample variations in staining intensity.
siRNA gene silencing and NOTCH3 blocking
Ab treatment
Notch3 knockdown was carried out using GeneSolution
siRNA (Qiagen). A nonspecific siRNA (AllStars Negative
control; Qiagen) was used as a negative control. hESC-
derived SMCs were transfected with siRNA (40 nm for one
well of six-well plate) using DharmaFECT I transfection re-
agent (Thermo Scientific Dharmacon). The transfection was
repeated after 2 days and the mRNA and protein analyses
were performed after 24 and 48h, respectively. The efficiency
of NOTCH3 knockdown by siRNA was *70%, and the
siRNA exhibited maximum gene knockdown effectiveness
after the second transfection (Supplementary Fig. S5).
A blocking antibody specific for NOTCH3 (AbN3; 10 ng/
mL) given by Dr McCafferty [22] and a control anti-Desmin
antibody (AbDesmin;10 ng/mL) were added to the medium
of intermediate populations of LM and PM at day 5 and NE
at day 7. The treatment was repeated after 3 days and the
cells were harvested at day 7 and analyzed by qRT-PCR.
Western blot
Western blot analysis was performed as previously de-
scribed [9]. Primary antibodies used include polyclonal
rabbit anti-Notch3 1:1,000 (ab23426; Abcam), monoclonal
anti-smooth muscle a-Actin, 1:400 (DAKO), Calponin,
1:5,000 (CNN1, C2687; Sigma), and anti-b-actin 1:5,000
(A1978; Sigma).
Mouse aortic staining and quantification
The Notch3 - / - mouse strain was provided by Dr. Tho-
mas Gridley [23]. Studies on these mice were approved by
the Nationwide Children’s Hospital Animal Use and Care
Committee. Notch3+ /- mice were crossed to produce wild-
type and Notch3- /- embryos for analysis. Embryos were
fixed in 4% paraformaldehyde overnight at 4C, embedded in
paraffin, and sectioned at 8mm. For immunohistochemistry,
sections were blocked with 10% goat serum and 1% BSA
diluted in PBS with 0.5% Triton-X-100 for 1 h at room tem-
perature. Sections were then incubated with primary antibody,
anti-Acta2 (1:1,000, Cat: A2547; Sigma), overnight at 4C,
followed by staining with the appropriate Alexa Fluor–
conjugated secondary antibody (1:500; Invitrogen) in PBT
for 1 h at room temperature, counterstained with 4¢,6-dia-
midino-2-phenylindole (DAPI), and mounted in Vectashield
mounting medium (H-1400; Vector Laboratories). Pictures
were taken using a fluorescence microscope (1·51; OLYM-
PUS). Fluorescence of desired vessels was separated out and
subtracted from the background to quantify Acta2 intensity.
SMA and DAPI costained cells were counted with Cell Count
plug-in. Fluorescent images were analyzed with ImageJ soft-
ware by an observer blinded to sample genotype. Arch mea-
surements of Acta2 staining in mouse sections were normalized
to corresponding paired dorsal aortas on the same section to
correct for intersample variations in staining intensity.
Statistical analysis
Results are presented as mean – SD of three independent
experiments unless otherwise stated. Statistical analysis was
performed using Student’s t-test.
Results
Expression of Notch pathway components
during lineage-specific SMC development
The H9 hESC line was differentiated into the three early
lineages from which most vascular SMCs arise, as we pre-
viously described [9]. For NE differentiation, hESCs were
incubated with fibroblast growth factor 2 (FGF2, 12 ng/mL)
and the activin/nodal inhibitor SB431542 (10mM) for 7 days
to generate the NE intermediate population, which expresses
the specific marker PAX1 (Fig. 1A and Supplementary Fig.
S1C). For mesoderm subtype differentiation, we used a combi-
nation of FGF2 (20 ng/mL), phosphoinositide 3-kinase (PI3K)
inhibitor (LY294002, 10mM), and bone morphogenetic protein
4 (BMP4, 10ng/mL) for 36h to generate an early mesoderm
intermediate population. For subsequent specificationofLMand
PM, the early mesoderm population was respectively incubated
for 3 days with FGF2 (20ng/mL) and LY294002 (10mM) to
generate paraxial mesoderm progenitors expressing the specific
marker TBX6 or with FGF2 (20ng/mL) and BMP4 (50 ng/mL)
to generate a lateral mesoderm intermediate, which expresses
NKX2.5 as a specificmarker (Fig. 1A and Supplementary Fig.
S1A, B). Further treatment with a combination of PDGF-BB
(10 ng/mL) and TGF-b1 (2 ng/mL) for 12 days promoted the
differentiation of all the intermediate populations into origin-
specific SMCs, which express high levels of specific SM
markers, including Calponin (CNN1) and SM myosin heavy
chain (MYH11) (Fig. 1A and Supplementary Fig. S1A–C).
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We assessed the RNA expression of the four human notch
receptors (NOTCH1, NOTCH2, NOTCH3, and NOTCH4),
the delta-like (DLL1, DLL3, and DLL4), and jagged (JAG1
and JAG2) ligands, and the downstream effectors, HES1,
HEY1, and HEY2, by quantitative RT-PCR at different time
points during the differentiation of origin-specific SMC
subtypes (Fig. 1B–G and Supplementary Fig. S1D–I). Spe-
cifically, RNA levels were measured at day 0 (pluripotent
stem cell stage; hESC); at the intermediate population stage,
day 5 (D5) for LM and PM and day 7 (D7) for NE; at the
intermediate stage of differentiating smooth muscle (DSM)
at day 12 (D12) for LM and PM subtypes and at day 14
(D14) for NE lineage; at the end of the differentiation
protocol at day 17 (D17) for LM and PM and at day 19
(D19) for NE-SMCs; and finally at the mature smooth
muscle stage (MSM; day 50) after a further 30 days of
FIG. 1. NOTCH3, JAG1, and HES1 show a similar expression trend during the differentiation of SMCs of neuroectoderm
(NE) origin. (A) A schematic representing the timescale of SMC differentiation from hESC to the three different origin-
specific subtypes: lateral mesoderm (LM), paraxial mesoderm (PM), and NE. RNA was extracted at the hESC stage (day 0),
at the intermediate population stage (day 5/7), at the early SMC differentiation stage (day 12/14), at end of the differen-
tiation protocol (day 17/19), and at the mature stage (day 50) after 30 days of culture in serum-containing media. The
transcript levels of Notch receptors (NOTCH1, NOTCH2, NOTCH3, and NOTCH4; B–E), ligands (JAG1; F), and down-
stream effectors (HES1; G) were detected by qRT-PCR. The expression was calculated relative to the housekeeping genes,
GAPDH and PBGD. The asterisk indicates a statistically significant difference in the expression of NOTCH3 in the NE-
SMCs in comparison with LM and PM-SMC lineages; *P < 0.05. (H, I) Flow cytometry analysis demonstrated that NE-
SMCs at the early differentiation stage (day 14; H) were highly positive for NOTCH3 at protein levels (NOTCH3-FITC),
while at the mature stage (day 50; I), the PM-SMC was more positive for NOTCH3. Values represent mean –SD (n= 3).
DSM, differentiating smooth muscle cells; IP, intermediate populations; MSM, mature smooth muscle cells; NE-SMC,
neuroectoderm-derived SMC; qRT-PCR, quantitative real-time polymerase chain reaction; PM-SMC, paraxial mesoderm-
derived SMC; SMC, smooth muscle cell.
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culture in serum-containing media. Notably, at the DSM
stage, among the four NOTCH receptors, only NOTCH3
showed a statistically significant difference in expression
level between different lineages, with higher expression
exclusively in developing NE-SMCs both at RNA and
protein levels (Fig. 1D, H). A comparable expression pattern
for NOTCH3 was seen in the hiPSC line at RNA level as
shown in Supplementary Fig. S2. Similarly Jagged1 (JAG1)
and Hes-1 (HES1) RNA levels increased specifically in the
NE-SMC subtype at day 14 (Fig. 1F, G). These data dem-
onstrate a lineage-specific expression pattern for JAG1,
HES1, and NOTCH3 in the developing SMCs of NE origin
and raise the possibility that JAG1 and HES1 may be
downstream of Notch3 signaling.
Conversely, in mature SMCs after 30 days of culturing in
serum-containing medium, the expression of most Notch
components, including NOTCH1, NOTCH2, NOTCH3,
JAG1, HEY1, and HES1, increased substantially in PM-
SMCs (Fig. 1B–D, F, G and Supplementary Fig. S1H).
NOTCH3 increased expression was also observed at the
protein level by flow cytometric analysis as shown in Fig.
1I. Collectively, these in vitro data suggest that NOTCH3
expression varies according to the lineage and the stage of
SMC development.
NOTCH3 is highly expressed in fetal
descending aorta
To determine whether our in vitro findings had any phys-
iological relevance, we initially stained sequential sections of
human 8–9 week fetal aortas with a specific antibody for
NOTCH3 (Fig. 2A–D). The same sections were co-stained
with an antibody specific for smoothmusclea-actin (ACTA2)
to visualize the layer of SMCs in the aortic wall (Fig. 2E–H).
Quantification of NOTCH3 immunostaining revealed a
higher expression in the DTA (Fig. 2N) and in the DAA (Fig.
2N and Supplementary Fig. S3A), which are populated by
PM-SMCs, in comparison with the ascending aorta (AA),
pulmonary artery (PA), and the heart (Supplementary Fig.
S3B). In agreement with the protein distribution, NOTCH3
mRNA levels were higher in the DTA and DAA portions of
the aorta (Fig. 2O). Based on these data, we speculate that the
in vitro serum matured SMCs (day 50; Fig. 1D, I), which also
show higher NOTCH3 expression in PM-SMCs than in the
other lineages, are comparable in development with SMCs in
the 8–9 week or older fetal aorta.
Taken together, these data strongly suggest that our
hESC-derived lineage-specific SMCs have relevance for
modeling and predicting in vivo developmental events.
Mature SMC marker expression is affected
by NOTCH3 knockdown
To investigate the role of Notch3 in serum matured SMCs,
which are comparable to the human fetal aortic SMCs,
NOTCH3 expression was knocked down using a siRNA-
mediated approach. A specific siRNA (siRN3) was trans-
fected in fully differentiated MSM (day 50; SMC), which had
been cultured in serum-containing media for 1 month (Fig.
3A), the cells were then harvested, and the expression levels
for SMC markers were assessed. SiRN3 was successful in
knocking down the NOTCH3 gene expression by *70%
when compared with the control treated with scrambled
siRNA as shown in Fig. 3B.
Interestingly, effective downregulation of NOTCH3 neg-
atively affected the expression of both early SMC markers,
including Calponin (CNN1), SM a-actin (ACTA2), and
SM22 (TAGLN; Fig. 3C–E), and late SMC markers, in-
cluding SM myosin heavy chain (MYH11) and Smoothelin
(SMTN; Fig. 3F, G) in PM-SMCs, while lateral mesoderm-
derived SMCs showed no difference from the control. Pro-
tein analysis by western blot also confirmed a reduction of
ACTA2 in the PM-SMC sample upon siRN3 treatment (Fig.
3H). Similar to PM-SMCs, in SMCs of NE origin, CNN1,
TAGLN, and SMTN showed significant decreased RNA levels
upon NOTCH3 knockdown (Fig. 3C, E, G). However,
NOTCH3 siRNA treatment had no effect on MYH11 ex-
pression (Fig. 3F) and a nonsignificant effect onACTA2 either
at RNA or protein levels (Fig. 3D, H) in NE-SMCs. Although
it has been shown that both these genes are direct targets of
Notch ICD activity, previous studies have not carried out a
lineage-specific analysis of Notch induction [24,25]. Our re-
sults demonstrate that regulation of SMC markers by Notch3
is critically dependent on cell lineage. Moreover, JAG1 was
downregulated upon Notch3 knockdown exclusively in the
NE subtype (Supplementary Fig. S4A). Thus, JAG1 expres-
sion specifically depends on Notch3 function in NE-SMCs
and raises the possibility that it in turn activates Notch3.
Neither JAG1 nor JAG2 expression was affected in PM-
SMCs by NOTCH3 knockdown (Supplementary Fig. S4A,
B); however, a significant downregulation of HEY1 was ob-
served (Supplementary Fig. S4C). From these observations,
we conclude that Notch3 is able to control the expression of
SM markers in mature SMC lineages of NE and PM origins,
although not in lateral mesoderm-derived SMCs. Moreover,
the possible positive feedback loop between Notch3 and its
ligand, Jagged1, is specific for the NE-SMCs.
NOTCH3 is required for SMC marker expression
during early SMC development from NE in vitro
We next investigated the role of Notch3 in early SMC
development, again using the siRNA-mediated knockdown
approach. siRN3 was transfected at day 4 in lateral meso-
derm and PM precursors, and then repeated at day 6 (Fig.
4A). Similarly the NE intermediate population was trans-
fected once at day 6 and a second time at day 8 (Fig. 4A). A
double transfection was more effective in reducing NOTCH3
at both RNA and protein levels than a single transduction as
shown in Supplementary Fig. S5A and B. Figure 4B shows
that NOTCH3 gene expression was reduced by *70% fol-
lowing siRN3 treatment. We observed that a range of smooth
musclemarkers, including earlymarkers (CNN1,ACTA2, and
TAGLN; Fig. 4C–E) and late markers (MYH11 and SMTN;
Fig. 4F, G), were strongly downregulated upon knockdown
of NOTCH3, specifically in NE-SMCs. In addition, protein
analysis by western blot and immunofluorescence confirmed
that the downregulation of both ACTA2 and CNN1 occurs
predominantly in NE lineage upon NOTCH3 knockdown
(Fig. 4H and Supplementary Fig. S6C). Furthermore, JAG1
and HES1 appear to be negatively affected by NOTCH3
downregulation in NE-SMCs (Supplementary Fig. S6A, B).
This is consistent with our previous observations in ma-
ture SMCs, which support a positive feedback mechanism
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between components of the Notch pathway, which in turn
controls the expression of specific SMC markers.
To confirm the importance of Notch3 in regulating the
expression of SM markers in the NE-SMC lineage, we used
a specific antibody to block exclusively Notch3 activity
(AbN3; Supplementary Fig. S7) [22]. The blocking anti-
body was added to the intermediate populations at day 5
for lateral mesoderm and PM and at day 7 for NE (Sup-
plementary Fig. S7A), and after 7 days the cells were
harvested and tested for SM marker expression. Similar to
our previous findings using siRNA, a set of SM markers
was downregulated only in NE-SMCs after the treatment
with AbN3 when compared with control cells treated with
an antibody raised against Desmin (AbDesmin; Supple-
mentary Fig. S7B–F). Thus, using two different ap-
proaches, we have confirmed that Notch3 activity is critical
for the early expression of SM markers exclusively in
SMCs of NE origin.
ACTA2 expression in aortic SMCs is reduced
in Notch3-null mice
Although the Notch3-null embryo has not been reported
to have a phenotype before birth [23,26], our data reveal a
specific requirement for Notch3 in early NE-SMCs. These in
vitro findings thus predict a physiological role in SMC
FIG. 2. Immunostaining and transcript expression analysis in human fetal aorta shows higher level of NOTCH3 in the descending
portion of the aorta. (A–L) Sequential sectionswere taken from cryopreserved tissue of human fetal aorta of 8–9weeks embryos. The
sections were costained with a specific antibody for NOTCH3 (green; A–D) and an antibody for ACTA2 (red; E–H). Low-
magnification images of a single section show staining for NOTCH3 (A), ACTA2 (E), and merge (I) in the ascending aorta (AA),
pulmonary artery (PA), and descending thoracic aorta (DTA). High magnification of NOTCH3 staining showed higher intensity in
DTA (D) than AA (B) and PA (C). (M) Schematic representing the section orientation and the different aortic regions. (N)
Quantification of NOTCH3 staining intensity in different aortic regions is expressed relative to the expression in DTA (n=3). The
asterisks indicate statistically significant difference betweenDTAandPA. **P<0.001. (O)RNAfromeach dissected portion of aorta
was extracted and the NOTCH3 transcript level was quantified by qRT-PCR. Values represent mean–SD (n=2). The expression
was calculated relative to the housekeeping genes, GAPDH and PBGD. DAA, descending abdominal aorta. Scale bar=50mm.
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development around the aortic arches in the early embryo.
Consequently, to validate the in vivo significance of our
hESC-derived SMC model, we measured the intensity of
SM a-actin (Acta2) expression in SMCs of aortic arch
sections of E10.5 Notch3-null mice (Fig. 4J; n = 8) and
compared them with the corresponding sections from wt
mice (Fig. 4I; n = 10). Since our in vitro model predicted
that there would be no change in dorsal aorta SM a-actin
staining (as this is PM-SMC), then in both Notch3-null and
wt sections, arch measurements were normalized to corre-
sponding paired dorsal aortas on the same section to correct
for intersample variations in staining intensity. Notch3-null
arch sections were found to have a significant decrease in
SM a-actin staining, in comparison with the wt (Fig. 4K).
Nevertheless, the number of SMCs did not differ between wt
and null embryos (expressed as DAPI staining quantification
of the SM a-actin positive cells; Supplementary Fig. S8),
implying a failure of SMC differentiation in the cells in-
vesting the aortic arches. Taken together, these data strongly
suggest that our hESC-derived lineage-specific SMCs have
relevance for modeling and predicting in vivo develop-
mental events.
Discussion
Notch signaling is known to be important for vascular
development and especially for the regulation of SMC dif-
ferentiation. However, vascular SMCs are heterogeneous
and arise from multiple embryonic origins, and to date there
is a paucity of data on whether the embryonic lineage of
SMCs influences their response to Notch. Furthermore, there
are few or no human developmental studies and it is unclear
to what extent data from the mouse models accurately re-
flect events in the human vasculature. In this study, we have
used an in vitro human ESC-based system to investigate the
effects of Notch3 on SMCs with distinctive embryological
origins. We have also correlated our in vitro findings with
observations from selected regions of human fetal aortas
with corresponding embryological origins. Importantly, our
in vitro model predicted a previously undocumented neural
crest-specific phenotype in the developing aorta in the ab-
sence of Notch3 signaling, which was verified by observa-
tions in Notch3 null-mouse embryos.
Our model of hESC-derived SMCs shows that Notch
receptors, ligands, and downstream factors have unique
FIG. 3. Impaired late SMC differentiation in response to NOTCH3 knockdown in lineages where NOTCH3 is highly
expressed. (A) Mature SMCs cultured for 30 days in serum-containing media were transfected with a specific siRNA for
NOTCH3 (siRN3) and with a scrambled siRNA as control (siScr). Cells were harvested after 2 days and transcript levels
were quantified by qRT-PCR. (B) NOTCH3 expression was significantly reduced in the three lineages upon siRN3 treat-
ment. CNN1 (C), TAGLN (E), and SMTN (G) levels were downregulated in PM-SMC and NE-SMC lineages in siRN3
samples. ACTA2 (D) and MYH11 (F) expressions were significantly reduced in PM-SMCs only upon siRN3 treatment. The
expression was calculated relative to the housekeeping genes, GAPDH and PBGD. Values represent mean –SD (n = 3). The
asterisks indicate statistically significant differences in comparison with the scrambled siRNA transfected cells; *P< 0.05;
**P< 0.001. (H) Western blot analysis showed reduction of ACTA2 in PM-SMC siRN3-treated samples only. b-actin was
used as loading control (n = 2).
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expression patterns in the different origin-specific SMC
subtypes. Interestingly, NOTCH3 was the only NOTCH
receptor to show lineage-specific expression changes during
SMC development. In addition, NOTCH3 and its ligand,
JAG1, share a similar expression trend in developing and
mature SMCs. In particular, NOTCH3 was found to be
highly expressed in PM-SMCs, which have been cultured
with serum-containing media for 30 days. This stage of our
in vitro model corresponded to the physiological expres-
sion of NOTCH3 in the aortic SMC layer of the 8–9 week
human fetus, where Notch3 mRNA and protein levels
were found to be higher in areas populated by SMCs of
somitic origin, such as the DTA and DAA than other aortic
regions. These in vitro–in vivo comparisons allow us to
begin to estimate the developmental stage and maturity of
the hESC-derived SMCs, a common challenge for many
FIG. 4. Lineage-specific early NOTCH3 dependence in vitro predicts neural crest phenotype in Notch3-null embryos. (A)
siRN3 and a siScr as control were transfected twice in intermediate population for LM and PM at days 4 and 6 and for NE at
days 6 and 8 as shown in the schematic. Cells were harvested at day 8/10 and transcript levels were quantified by qRT-PCR.
(B) NOTCH3 was effectively knocked down in the three lineages upon siRNA treatment. CNN1 (C), ACTA2 (D), TAGLN
(E), MYH11 (F), and SMTN (G) were negatively affected by NOTCH3 knockdown in the SMCs of NE origin. The
expression was calculated relative to the housekeeping genes, GAPDH and PBGD. Values represent mean – SD (n = 3). The
asterisks indicate statistically significant differences in comparison with the siScr transfected cells; *P < 0.05; **P< 0.001.
(H)Western blot analysis of NOTCH3, ACTA2, and CNN1 in siScr and siRN3 samples. b-actin was used as loading control
(n = 2). (I, J) Transverse sections of wt and Notch3- /- embryos at E10.5 were stained for Acta2. (K) Comparison of Acta2
staining intensity in the Arch between wt (n= 10) and Notch3 null (n = 8) shows significant decrease of expression in the
latter (*P < 0.05). Ao, dorsal aorta.
THE ROLE OF NOTCH3 IN SMC LINEAGE DEVELOPMENT 853
types of in vitro-generated tissues in the field of regener-
ative medicine [27,28].
On the other hand, during early development, we ob-
served that NOTCH3 and JAG1 were upregulated exclu-
sively in NE-SMCs, suggesting a specific role for Notch3 in
the early development of this subtype. Consequently, to
explore the importance of Notch3 in the different SMC
subtypes at different developmental stages, we have per-
formed siRNA-mediated knockdown studies in both mature
and developing SMCs. Notably, our results show that at the
serum maturation stage, Notch3 is required for maintaining
the expression of SMC-specific markers in SMCs of PM
origin. This is consistent with previous observations in
Notch3-null mice, which display SMC defects associated
with postnatal maturation in areas of somitic origin, such as
the caudal artery of the tail [18,29].
When NOTCH3 is knocked down at an earlier stage of
SMC development, the expression of SMC-specific markers
was significantly downregulated exclusively in the NE line-
age. This result was further confirmed by inhibiting the
NOTCH3 activity with a specific blocking antibody. These
studies demonstrate both lineage-specific and developmental
stage-specific requirements for Notch3 signaling in SMC de-
velopment. Importantly, SMC marker expression levels were
not totally abolished by NOTCH3 knockdown in vitro or in
the Notch3-null mouse, suggesting that NOTCH3 is not the
sole regulator of SMC differentiation and maturation. This
confirms the involvement of other signaling pathways, which
may include other Notch receptors [17] or NOTCH-indepen-
dent pathways, in the complex process of SMC development.
Interestingly, previous studies have shown impaired va-
soconstriction of the cerebral arteries in knockout mice,
suggesting that Notch3 is required for the functional integ-
rity of neural crest-derived vascular SMCs in adult animals
[18]. However, no vascular phenotype has been reported in
the Notch3-null embryo [23,26], suggesting that vascular
defects manifest postnatally. Remarkably, expression of
dominant negative mastermind-like in neural crest-derived
tissues using a cre-based system did inhibit SMC differen-
tiation around the aortic arches in mouse embryos [30].
However, this method inhibits signaling through all Notch
receptors and does not clarify the role of Notch3.
In this study, we have shown for the first time that Notch3
activity is required during early SMC development, and that
potentially in the absence of Notch3, the differentiation of
NE-SMCs may be already compromised during embryonic
development. Importantly, we have confirmed the physio-
logical relevance of our in vitro findings, by analyzing the
intensity of Acta2 staining in the aorta of E10.5 Notch3-null
mice. Notably, Acta2 immunostaining is markedly reduced
in the aortic arch, in accordance with our in vitro data, im-
plying that Notch3 has an exclusive role during the early
development of SMCs originated from neural crest precur-
sors. Taken together, these findings illustrate the power of
our in vitro model for detecting lineage-specific develop-
mental phenotypes that may have been missed in studies on
embryos.
In our in vitro model, we also observed a reduction of
JAG1 expression levels in response to Notch3 inhibition in
both developing and mature SMCs of NE origin, suggesting
the requirement of a Notch-induced positive feedback loop
for SMC differentiation, in agreement with previous find-
ings [29,31]. Indeed, this is a common feedback modality for
Notch, which also induces another ligand, DLL4, in cardiac
development [32,33]. These positive feedback pathways for
Notch permit lateral induction and the establishment of a
developmental field, in our case for vascular SMCs.
In differentiated SMCs, in addition to its effects on the
PM lineage, NOTCH3 inhibition also reduced the expression
of SMC markers in the NE subtype, with the only exception
of MYH11. The diverse responses to NOTCH3 knockdown
observed in different SMC lineages may be due to the po-
tential redundancy between Notch receptors and ligands,
which function synergistically with the SRF/myocardin
complex or independently to activate or repress the ex-
pression of SMC markers [17,24]. This may also explain
why the SMC phenotype is not seen in all the vessels of
Notch3-null adult mice and why Acta2 expression is only
partially reduced in the developing NE-SMCs, suggesting
that other components of the Notch pathway may to some
extent compensate for the absence of Notch3 in a lineage-
dependent manner.
Ultimately, our findings provide some insight into the
Notch receptor–ligand specificity in regulating the differen-
tiation of different SMC lineages and support the functional
importance of NOTCH3 in human vascular development.
These findings have potential clinical relevance since mu-
tations in NOTCH3 cause the late-onset genetic vascular
condition, Cerebral Autosomal Dominant Arteriopathy with
Subcortical Infarcts and Leukoencephalopathy (CADASIL)
[34,35]. In the brain, the pathology is characterized by pro-
gressive degeneration of SMCs in small arteries and multiple
cerebral infarcts. The pathognomonic finding is the accu-
mulation of a granular osmiophilic material, known as GOM,
found in vascular SMCs throughout the body and may be
detected even in vessels isolated by skin biopsies. Despite
the wide distribution of GOM deposition, it is unclear why
the vascular complications appear to be limited to the brain.
Our hESC-derived SMC model supports a unique role for
Notch3 in the development of the NE-SMC lineage, pro-
viding the first human evidence of a direct correlation be-
tween the lineage-specific requirement for Notch3 in SMC
development and the site-specific pattern of pathology in
CASADIL syndrome.
In conclusion, our hESC-derived SMC model provides a
new and useful tool for studying human SMC development
with a high predictive value in vivo. A particular strength of
this system is the ability to investigate the role of the em-
bryonic lineage on developmental mechanisms, which may
also have relevance for understanding the regional distri-
bution of congenital and acquired vascular diseases.
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